Technology

Dedicated to Pioneering

We remain dedicated to pioneering innovative dosage forms to enhance pediatric pharmaceuticals.

The primary focus of our drug research revolves around product development in various domains related to children’s health. These include the treatment of pediatric hypertension, mental health conditions in children, pediatric tumors, and infectious diseases within the pediatric population.

Drug Delivery System

SD Platform Technology for Age-appropriate formulation. SD Platform Technology is Brillian's proprietary technology for Powder-for-Liquid dosages forms, which possesses Single-dose, Single-dispersing, and grittiness-free characteristics.

Childen Drug 505(b)(2)

Based on our SD Platform Technologies, to address the shortcomings of existing pediatric drug formulations, to meet the urgent but unmet needs in the pediatric therapeutic area, and to develop better compliant drug formulations that better match the physiological characteristics of children